Phase
Condition
Lung Cancer
Non-small Cell Lung Cancer
Adenocarcinoma
Treatment
N/AClinical Study ID
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Pathologically or cytologically confirmed of stage IIIa-IV pulmonary adenocarcinoma;
The efficacy evaluation of the first-line therapy is progression-free includingcomplete response(CR), partial response(PR) and stable disease(SD);
Age ≥18 years old;
Physical status score (ECOG PS) ≤ 2 scores;
Estimated life expectancy of at least 12 weeks;
Participants have no major organ dysfunction: hemoglobin ≥9 g/dL, absolute neutrophilcount (ANC) ≥1.5*109/L, platelets ≥100 *109/L,bilirubin ≤1.5ULN, alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 upper limitednumber(ULN) (AP, AST, ALT ≤5ULN is acceptable if liver has tumor involvement).INR≤1.5,APTT in the normal range( 1.2DLN-1.2ULN),creatinine ≤1.5ULN;
Planning for targeted maintenance.
Informed consent from the patient.
Exclusion
Exclusion Criteria:
The efficacy evaluation of the first-line therapy is progressive disease(PD);
Patient with other malignant tumor except NSCLC 5 years previous to study entry;
Patient has already received chemotherapy or other anticancer treatment;
Estimated life expectancy less than 12 weeks;
Brain metastasis (controlled brain metastasis and steroid free need is excluded);
History of cardiovascular disease: Congestive Heart Failure > grade II inNYHA.Unstable angina patients (have angina symptoms in rest) or a new occurrence ofangina (began in the last 3 months) or myocardial infarction happens in the last 6months;
Pregnant or child breast feeding women;
Mental or cognitive disorders;